课题基金 / 基金详情

RANDOMIZED DOUBLE-BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP-266 AND 1592U

RANDOMIZED DOUBLE-BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP-266 AND 1592U
硫酸茚地那韦、DMP-266 和 1592U 的随机双盲 II 期研究
批准号:
6297812
负责人:
MARGRIT CARLSON
金额:
$0.19万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

MARGRIT CARLSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ACTG 320 was a clinical trial of anti-HIV medications which compared the use of a three drug combination Zidovudine (ZDV)+Indinavir(IDV) to a two drug combination (ZDV + 3TC), in persons who ahd previously taken Zidovudine ZDV. The three drug combination included two medications that were potent and new, as compared to the two drug combination which had only one new drug. This study showed that the three drug combination was more effective.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF QUADRIVALENT: HIV
FLUCONAZOLE AS CHRONIC SUPPRESSIVE VS EPISODIC THERAPY IN HIV PATIENT
COMPARISON OF THE VIROLOGIC EFFECACY OF NELFINAVIR AND/OR DMP-266 IN COMBINATION
ANTIVIRAL ACTIVITY OF T 20 ADMINISTERED TO HIV 1 POSITIVE ADULTS
海外基金